Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax

Pharmacology Research and Perspectives

Volumn 3, Issue 5, 2015, Pages

  Ackler, Scott ^a   Oleksijew, Anatol ^a   Chen, Jun ^a   Chyla, Brenda J ^a   Clarin, Jerry ^a   Foster, Kelly ^a   McGonigal, Thomas ^a   Mishra, Sasmita ^a   Schlessinger, Sally ^a   Smith, Morey L ^a   Tahir, Stephen K ^a   Leverson, Joel D ^a   Souers, Andrew J ^a   Boghaert, Erwin R ^a   Hickson, Jonathan ^a  

^a ABBVIE INC   (United States)

Author keywords

Apoptosis; Bcl 2 family proteins; bioluminescent imaging; drug therapy; leukemia lymphoma; systemic engraftment

Indexed keywords

BENDAMUSTINE; CASPASE 3; CYCLOPHOSPHAMIDE; DOXORUBICIN; NAVITOCLAX; PREDNISOLONE; PROTEIN BCL 2; RITUXIMAB; VENETOCLAX; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CELL VIABILITY ASSAY; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; HEMATOLOGIC DISEASE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KINETICS; MANTLE CELL LYMPHOMA; NECROSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SKELETAL MUSCLE; SPECTROPHOTOMETRY; TUMOR ENGRAFTMENT; TUMOR REGRESSION; TUMOR VOLUME;

EID: 84975769164     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.178     Document Type: Article

References (27)

1. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. (2010). The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66: 869–880.
2. Ackler S, Mitten M, Chen J, Clarin J, Foster K, Jin S, et al. (2012). Navitoclax (ABT-263) and bendamustine +/- rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol 167: 881–891.
3. Butterworth M, Vogler M, Dyer MJ, Cohen GM (2009). Response: microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia. Blood 114: 2561.
4. Chiorazzi N, Rai KR, Ferrarini M (2005). Chronic lymphocytic leukemia. N Engl J Med 352: 804–815.
5. Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF, et al. (2012). The Bcl-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood (ASH Annual Meeting Abstracts) 120: a304.
6. Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WM, et al. (2013) The Bcl-2 inhibitor ABT-199 (GDC-0199) is active and well tolerated in patients with relapsed/refractory mantle cell lymphoma and other non-Hodgkin's lymphomas. EHA Congress Abstracts P849.
7. Gill S, Herbert KE, Prince HM, Wolf MM, Wirth A, Ryan G, et al. (2009). Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 147: 83–88.
8. Hickson J (2009). In vivo optical imaging: preclinical applications and considerations. Urol Oncol 27: 295–297.
9. Hickson J, Ackler S, Klaubert D, Bouska J, Ellis P, Foster K, et al. (2010). Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin. Cell Death Differ 17: 1003–1010.
10. Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, de Schouwer PJ, et al. (1997). Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 11: 64–72.
11. Kaijzel EL, van der Plujim G, Lowik CW (2007). Whole-body optical imaging in animal models to assess cancer development and progression. Clin Cancer Res 13: 3490–3497.
12. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577–1579.
13. Liem NL, Papa RA, Milross CG, Schmid A, Tajbakhsh M, Choi S, et al. (2004). Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103: 3905–3914.
14. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, et al. (2008). Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 1181–1189.
15. McGrath J, Drummond G, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573–1576.
16. O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT (2010). Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol 220: 317–327.
17. Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, et al. (2008). Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 51: 6902–6915.
18. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. (2012). Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30: 488–496.
19. Sekiguchi N, Kobayashi Y, Yokota Y, Kusumoto S, Tanimoto K, Watanabe T, et al. (2005). Follicular lymphoma subgrouping by fluorescence in situ hybridization analysis. Cancer Sci 96: 77–82.
20. Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Miller TP, et al. (2013). Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood (ASH Annual Meeting Abstracts) 122: a872.
21. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19: 202–208.
22. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421–3428.
23. Tsujimoto Y, Finger LR, Yunis J, Nowel PC, Croce CM (1984). Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226: 1097–1099.
24. L and BCL2A1 induces approximately 1 000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113: 4403–4413.
25. Wei MC (2004). Bcl-2-related genes in lymphoid neoplasia. Int J Hematol 80: 205–209.
26. Weissleder R, Pittet M (2008). Imaging in the era of molecular oncology. Nature 452: 580–589.
27. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. (2010). Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase I dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11: 1149–1159.